| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514543000 | Z forms a phenoxy alkyl or phenoxy alkenyl radical | 32 |
| 20090030077 | Novel Fenofibrate Formulations and Related Methods of Treatment - The invention provides novel omega-3 oil liquid formulations of fenofibrate. These formulations can be substantially free of any food effect, effective in small volumes, and readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oil as the major ingredient, they not only provide anithypercholesterolemic and antihypertriglyceridemic effects due to the fenofibrate active ingredient, they also provide recommended daily dosages of omega-3 oils (i.e., approximately 1 gram of omega-3 oil per day), or a portion thereof. | 01-29-2009 |
| 20100048701 | AMIDE COMPOUND AND USE THEREOF FOR CONTROLLING PLANT DISEASES - Disclosed is an amide compound represented by the formula (1) below, which has excellent plant disease controlling activity. | 02-25-2010 |
| 20100048702 | PREVENTION OF NEUTROPHIL RECRUITMENT - Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II. | 02-25-2010 |
| 20100056627 | PHARMACEUTICAL COMPOSITIONS OF ALKYL GALLATES - It is intended to reinforce the anti-fungal, anti-viral and anti-bacterial activities of alkyl gallates, and to provide a new technology and means which allow the solubilization of the alkyl gallates in water. | 03-04-2010 |
| 20100105772 | USE OF NOVEL LIPID MEDIATORS TO INHIBIT ANGIOGENESIS - The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of AA containing compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- and tri-hydroxy derivatives of AA (lipoxins, aspirin-triggered epi-lipoxins) that diminish, prevent, or eliminate NV, hemangiogenesis and/or angiogenic condition(s) of corneal tissue. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification. | 04-29-2010 |
| 20100120909 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF - The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like). | 05-13-2010 |
| 20100130605 | Use of Derivatives of Sinapinic Acid and Compositions Comprising Such Derivatives - The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. The invention furthermore relates to specific substances. | 05-27-2010 |
| 20100184856 | Novel Compounds and Uses Thereof for Treating Inflammation and Modulating Immune Responses - The present invention provides compounds, and compositions comprising these compounds, which have immunomodulatory activity and/or anti-inflammatory activity. | 07-22-2010 |
| 20100190855 | ORGANIC COMPOUNDS - A compound of formula (I) wherein Y is oxygen or sulfur, and X | 07-29-2010 |
| 20100197784 | NOVEL CURCUMIN ANALOGUES AND USES THEREOF - The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to induce androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction. Examples of androgen-related afflictions include, but are not limited to, baldness, hirsutism, behavioral disorders, acne, and uninhibited spermatogenesis wherein inhibition of spermatogenesis is so desired. | 08-05-2010 |
| 20110015266 | LYOPHILIZED NANOEMULSION - The present invention relates to a lyophilised nanoemulsion comprising a lipophilic phase and one or more sucrose fatty acid esters, to the nanoemulsion which can be prepared from the lyophilised nanoemulsion by redispersion, and to a process for the preparation of the lyophilised nanoemulsion. | 01-20-2011 |
| 20110201681 | CLEANSING BARS - A cleansing bar composition comprising a soap; and a wax having a melting point of about 50° C. to about 75° C., sunflower oil, and myristyl myristate. In one embodiment, the wax is beeswax. The combination of the wax, the sunflower oil, and myristyl myristate allows for the deposition of a hydrophobic material to skin when in use. | 08-18-2011 |
| 20120010286 | PREVENTION OF NEUTROPHIL RECRUITMENT - Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II. | 01-12-2012 |
| 20120029074 | CONTROLLING TRANSGENE EXPRESSION ACROSS THE SKIN - The invention relates to the use of a skin permeating compound such as phloretin for controlling transgene expression under control of the | 02-02-2012 |
| 20120046360 | FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF - A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described. | 02-23-2012 |
| 20120129931 | CAFFEIC ACID DERIVATIVES AND THEIR USE IN IMPROVING NEURONAL CELL VIABILITY - This invention relates to caffeic acid derivatives and improving viability of neuronal cells by contacting neuronal cells by caffeic acid derivatives as shown in the specification. | 05-24-2012 |
| 20120129932 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF - The invention concerns compositions comprising substituted 1,3-diphenylprop-2-en-1-one derivatives designed for therapeutic use. The inventive compositions are useful in particular for preventing or treating cardiovascular diseases, syndrome X, Ia restenosis, diabetes, obesity, hypertension, inflammatory diseases, cancers or neoplasms (benign or malignant tumors), neurodegenerative, dermatological diseases and disorders related to oxidative stress, for preventing or treating the effects of ageing in general and for example skin ageing, in particular in the field of cosmetics (occurrence of wrinkles and the like). | 05-24-2012 |
| 20120149770 | Antimicrobial Preservation of Propofol Emulsions - The invention provides intravenous formulations of propofol in an oil-in-water emulsion, having a combination of preservatives. | 06-14-2012 |
| 20120149771 | METHOD FOR TREATING AIRWAY HYPER-RESPONSIVENESS WITH LIPOXIN ANALOGS - The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway inflammation or infection as brought about by leukocyte-mediated injury from within. | 06-14-2012 |
| 20120178808 | FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF - A formulation comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients is described. Fenofibric acid, the physiologically acceptable salt or derivative thereof is preferably in the form of a molecular dispersion in these formulations. An advantageous process for their preparation, in particular by melt extrusion, and the use of this formulation for oral administration of fenofibric acid, a physiologically acceptable salt or derivative thereof are likewise described. | 07-12-2012 |
| 20120232140 | PHARMACEUTICAL COMBINATION OF PROSTAGLANDIN COMPOUND AND NSAID FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION - The present invention relates to a pharmaceutical combination comprising a prostaglandin compound and a NSAID. The present invention particularly relates to an ophthalmic composition comprising travoprost and bromfenac for the treatment of glaucoma and ocular hypertension. | 09-13-2012 |
| 20120277311 | LIPOXIN COMPOUNDS AND THEIR USE IN TREATING CELL PROLIFERATIVE DISORDERS - Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed. | 11-01-2012 |
| 20120302638 | ESTERS OF 4,5-DISUBSTITUTED-OXY-2-METHYL-3,6-DIOXO-CYCLOHEXA-1,4-DIENYL ALKYL ACIDS AND PREPARATION THEREOF - Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids were prepared chemically and/or enzymatically. Depending upon the ester, improved melanocyte cytotoxicity was achieved. Improved cytotoxicity characteristics are consistent with ester analogs being more physiologically compatible and less irritating to skin than their corresponding acids. | 11-29-2012 |
| 20130012579 | Anti-obesity Potential of Calebin A - The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-α), Interleukin-6 (IL-6) and Interleukin-1 (IL-1β). | 01-10-2013 |
| 20130303612 | SOLID DOSAGE FORM COMPRISING A FIBRATE - The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in a non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations. | 11-14-2013 |
| 20140296336 | SOLID RETARD FORMULATIONS BASED ON SOLID DISPERSIONS - A formulation comprising a melt-processed solid dispersion product comprising an active agent, a pharmaceutically acceptable thermoplastic polymer of N-vinyl lactams, and a pharmaceutically acceptable polyvinyl alcohol-polyalkylene glycol graft copolymer. A method for producing said formulation. | 10-02-2014 |
| 20140364497 | PHARMACEUTICAL COMPOSITIONS OF FENOFIBRATE - The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions. | 12-11-2014 |
| 20150306059 | METHOD FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA - Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides. | 10-29-2015 |
| 20150306060 | METHOD FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA - Disclosed is a therapeutic management method of hypercholesterolemia in mammals. More specifically, the present invention relates to a method of reducing high levels of circulating cholesterol (hypercholesterolemia) in the blood stream of mammals, said method involving step of administering therapeutically effective amounts of Calebin A to said mammals to bring about the effects of (i) reducing the amount of total blood cholesterol levels; (ii) reducing the concentrations of low density lipoproteins (LDL) and very low density lipoproteins (VLDL); (iii) increasing the concentrations of high density lipoproteins (HDL) and (iv) reducing concentrations of serum triglycerides. | 10-29-2015 |
| 20150313863 | Composition and Method for Treating Neuronal Ceroid Lipofuscinosis - Provided herein are methods for treatment of a neurodegenerative disease, such as neuronal ceroid lipofuscinosis including administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of an agent that mediates upregulation of TPP 1. | 11-05-2015 |
| 20160083327 | GPBP inhibition using Q2 peptidomimetics - Disclosed are compounds of formula: | 03-24-2016 |
| 20160199340 | CALEBIN A FOR HEPATIC STEATOSIS | 07-14-2016 |
